As a result, regulation at the kynurenine 3-monooxygenase enzyme determines the neurotoxic and neuroprotective potential of the kynurenine pathway.
22.
As a result, regulation at the kynurenine 3-monooxygenase enzyme determines the neurotoxic and neuroprotective potential of the kynurenine pathway.
23.
TDO catalyses the first and rate-limiting step of tryptophan degradation along the kynurenine pathway and thereby regulates systemic tryptophan levels.
24.
Docking of the kynurenine substrate into the active site suggests that Asn-333 and His-102 are involved in substrate binding.
25.
Kynurenine and its further breakdown products carry out diverse biological functions, including dilating blood vessels during inflammation and regulating the immune response.
26.
Kynurenine production is increased in Alzheimer's disease and cardiovascular disease where its metabolites are associated with cognitive deficits and depressive symptoms.
27.
KMO deficiency leads to an accumulation of kynurenine and to a shift within the tryptophan metabolic pathway towards kynurenine acid and anthranilic acid.
28.
KMO deficiency leads to an accumulation of kynurenine and to a shift within the tryptophan metabolic pathway towards kynurenine acid and anthranilic acid.
29.
The systematic name of this enzyme class is "'L-kynurenine : glyoxylate aminotransferase ( cyclizing ) " '.
30.
Kynurenine-3-monooxygenase deficiency is associated with disorders of the brain ( e . g . schizophrenia, tic disorders ) and of the liver.
